The spread of COVID-19 in the Americas driven by the Omicron variant of the virus reached levels of transmission never before seen during the pandemic, with cases doubling to 6.1 million over the past week, the Pan American Health Organization (PAHO) said on January 12.
If you are not happy with the results below please do another search
50 search results for:
Sparked by more than two years of virtual meetings due to the COVID-19 pandemic, Pfizer is cutting the company’s sales staff as more and more physicians’ offices and healthcare facilities prefer fewer face-to-face interactions with vendors. That preference for a virtual experience is expected to remain even after the pandemic wanes.
As part of a restructuring of the company’s research and development areas, Tokyo-based Daiichi Sankyo announced the closing of the Plexxikon R&D subsidiary in South San Francisco.
South Korean biotechnology firm ABL Biotechnologies signed a global licensing and exclusive collaboration agreement with Sanofi to develop and commercialize a new therapy candidate for Parkinson’s disease.
Biogen shares fell on January 12 after the Centers for Medicare and Medicaid Services (CMS) issued its draft national coverage decision for the company’s controversial Alzheimer’s drug Aduhelm.
Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company.
The Biden administration on January 12 announced a new set of measures to keep classes open, including doubling COVID-19 testing capacity in schools with 10 million more tests, as the Omicron variant spreads rapidly through the United States.
Pfizer Inc. said on Wednesday booster doses of the company’s COVID-19 vaccine can be administered along with its pneumonia vaccine and produced strong safety and immune responses in people aged 65 and above in a late-stage study.
India’s Bharat Biotech said on January 12 a booster shot of the company’s Covaxin COVID-19 vaccine administered six months after the last of two doses neutralizes both the Omicron and Delta variants of the coronavirus.
Japan recorded a surge in new coronavirus cases on January 12, with infections reaching four-month highs in the major metropolitan areas of Tokyo and Osaka as the Omicron variant spreads.